Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?

Wynendaele, Wim; Derua, Rita; Hoylaerts, Marc; Pawinski, Adam; Waelkens, Etienne; Bruijn, E. A. de; Paridaens, Robert; Merlevede, Wilfried; Oosterom, A.T. van

doi:10.1023/a:1008377921886

Cited by 107 publications

(72 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This ratio gives a rough estimation of how much VEGF is contained in the platelets 23,24 and we found that platelets of MMM patients contained four times more VEGF than those of healthy controls: median 0.99 pg per 10 6 platelets (range 0.6-3.1) vs 0.25 pg per 10 6 platelets (range 0.09-0.8) for MMM patients and controls respectively (Figure 2). Taken together, these data indicate that platelets may be a major source of VEGF both in MMM patients and in normal subjects and that platelets from patients contain a higher amount of VEGF.…”

Section: Resultsmentioning

confidence: 89%

Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis

et al. 2001

View full text Add to dashboard Cite

An increase of angiogenesis has been shown in idiopatic myelofibrosis with myeloid metaplasia (MMM) by microvessel density count method but evaluation of circulating angiogenic factors is still incomplete. In 31 patients affected by MMM and in 12 healthy subjects we evaluated the serum levels of VEGF (vascular endothelial growth factor) and correlated VEGF with clinical and laboratory features of disease. We found that MMM patients had circulating VEGF concentrations much higher than controls (median 1208 ng/ml vs 138 ng/ml, P Ͻ 0.0001). No correlation was found between VEGF and Hb, WBC, PLT, LDH, creatinine, bone marrow cellularity, fibrosis, splenomegaly, hepatomegaly, and therapy. However, in the subgroup of patients with a normal or low VEGF concentration, a direct correlation between VEGF and platelet count (r = 0.90, P = 0.002) was detected. Moreover, patients with a platelet count Ͻ300 × 10 9 /l had VEGF serum levels lower than patients with a higher PLT count (median VEGF 864 vs 1557 pg/ml, P = 0.001). In six patients and in eight controls we also had the opportunity to measure VEGF in the plasma and we calculated that VEGF concentration was much higher in platelet-rich than in platelet-poor plasma and that platetets of MMM patients contained four times more VEGF than those of healthy controls. These results indicate that VEGF is overproduced in MMM, thus confirming an increased angiogenic activity. Platelets are probably a major source of VEGF in MMM but not the only one. Leukemia (2001) 15, 976-980.

show abstract

Section: Resultsmentioning

confidence: 89%

Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis

et al. 2001

View full text Add to dashboard Cite

show abstract

“…The strong correlation between serum and plasma VEGF may reflect the fact that plasma VEGF levels are directly related to total blood VEGF levels and correspond to free VEGF after equilibration with platelet levels (George et al, 2000). Alternatively, we cannot rule out that the platelet VEGF released following a partial platelet degradation during plasma sampling and storage, may account for part of the EDTA plasma VEGF (Wynendaele et al, 1999).…”

Section: Prognostic Value Of Angiogenic Factors In Breast Cancer T Bamentioning

confidence: 99%

“…These levels have been correlated to the clinical course of the disease in several tumour types (Poon et al, 2001;Ugurel et al, 2001;Molica et al, 2002). As most serum VEGF is released from platelets during blood clotting, it has been suggested that plasma VEGF may be a better reflection of ongoing angiogenic activity, although this assumption has been challenged (Banks et al, 1998;Salven et al, 1999a;Wynendaele et al, 1999;George et al, 2000). To date, plasma VEGF has not been shown to be a better prognostic factor than serum VEGF in any solid tumour (Werther et al, 2002).…”

mentioning

confidence: 99%

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

et al. 2003

View full text Add to dashboard Cite

Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters. Tumour growth being angiogenesis-dependent, it has been hypothesised that the assessment of angiogenic factor production might reflect the clinical behaviour of cancer progression. This study was designed to investigate the clinical significance of vascular endothelial growth factor (VEGF) and interleukin 6 (IL-6) in hormone-refractory metastatic breast cancer. Serum and plasma concentrations of VEGF and serum concentration of IL-6 were measured in 87 patients with a fully documented history of metastatic breast cancer using an enzyme-linked immunoassay. All patients had detectable levels of VEGF, whereas 39% patients had detectable serum levels of IL-6. There was a positive correlation between IL-6 levels and the theoretical VEGF load of platelets (Po0.001). The presence of high levels of serum IL-6, but not VEGF, was significantly correlated to a shorter survival. In a multivariate analysis along with clinical prognostic parameters, serum IL-6 was identified as an independent adverse prognostic variable for overall survival (Po0.001). These results indicate that serum IL-6 levels correlate to poor survival in patients with hormone-refractory metastatic breast cancer. Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients.

show abstract

“…CTAD tubes contained sodium citrate, theophyllin, adenosine and dipyridamine allowing maximal platelet stabilization. The tubes were centrifuged within 15 min at 2500!g for 30 min at 4 8C [31]. The resulting plasma was separated and stored immediately at K80 8C.…”

Section: Blood Samples and Vegf Assaymentioning

confidence: 99%

“…The resulting plasma was separated and stored immediately at K80 8C. The technique of blood sampling and handling of probes has been published previously [10,31]. Thrombocyte count in CTAD plasma was measured and the amount was at the detection limit (!5000).…”

Section: Blood Samples and Vegf Assaymentioning

confidence: 99%

The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome

Wergin¹,

Roos²,

Inteeworn³

et al. 2006

Radiotherapy and Oncology

View full text Add to dashboard Cite

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?

Cited by 107 publications

References 32 publications

Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis

Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome

Contact Info

Product

Resources

About